Pharmaleaders Visionary Pharma Entrepreneur 2014 Awardee Dilip Surana led Microlabs aims $1 billion mark by 2016

Pharmaleaders Visionary Pharma Entrepreneur 2014 Awardee Dilip Surana led  Microlabs  aims $1 billion mark by 2016

 Bangalore based Top Pharma Major Microlabs known as Dolo Maker plans to scale new heights under Dilip Surana’s Visionary & Commanding Leadership, Dilip Surana to receive “Visionary Entrepreneur of the Year Award” at Pharma Leaders 2014 Historic Meet 

Dilip Surana

Sunday,7th December 2014, Mumbai, Maharashtra : It is widely believed that the consolidations in the Indian pharma sector is likely to continue, particularly among generic drug players and will drive shareholder value going forward.India-based pharmaceutical companies have majorly been absent from much of the recent M&A activities, partly because of their healthy growth outlooks. The global pharmaceutical industry will continue to undergo a pace of rapid consolidation to drive shareholder value; particularly in the case of companies seeking new growth platforms, against the backdrop of patent expirations.With many drugs going off patent in the US, Indian pharma companies would continue to experience strong growth in American market, indian pharma companies would continue to experience strong growth in the US over the medium-term. This would be driven by the sizable generic opportunity (drugs with brand value of $25-30 billion are expected to face generic competition) over the next 2-3 years.

As one of the recently industrialized nations, India has a fast-growing economy as well as an ever-expanding, ever-urbanized population, however its healthcare system still has a lot of potential for development. To Western readers, analyzing a healthcare system in the East seems daunting. It takes some of us decades to master an understanding of the healthcare system of our origin country. Nevertheless, there are several methods to approaching another country’s system. These include the exposition of some invariant principles that apply across various contexts, the application of existing frameworks for healthcare system analysis, appraisal of the major transitions underway in the country, and an analysis of the country’s public health issues. India faces challenges in pursuing each of these goals. With regards to cost, at least 70% of all healthcare is frequently financed out-of-pocket by the population. There is little health insurance or other forms of risk pooling, little regulation and accountability of providers, and a predominance of fee-for-service payment, all of which are associated with high costs. There is also questionable efficiency of much of the state healthcare system, and a great distrust of the public sector. Against the backdrop of the above challenges, Pharmaleaders has lined up top industry experts, Pharma Academia, Ministry Officials, Government Representative, Policy Makers & Medical Professionals under one platform both in india & abroad to debate & deliberate the complex issues of the industry & give a meaningful discussion on the Brand India & Make In India concept. More than 300 professionals will be participating the mega event where professionals from Middle East, Africa, Europe, Lation America will also be attending.The historic 7th Annual Pharmaceutical Leadership Summit & Business Leadership Awards 2014 to be held in a uniquely positioned full day program encompassing two themes “Make In India – Healthcare Reforms , Insurance,Innovations,Investments & Infrastructure” & Empowering India’s Developing Healthcare System – Investing the Healthcare Solutions of Tomorrow in difficult Times at the Sahara Star, Mumbai International Airport in Mumbai, India, on December,26th , 2014. This  historic Summit is supported by the Government of India at the Centre & is actively supported  by the Ministry of Health &  Family Affairs, Govt of India, Ministry of Commerce Pharmaceuticals , Government of india & host of other trade bodies.

Commenting on the Award Selection to Dilip Surana as “Visionary Entrepreneur of the Year Award” at pharmaleaders 7thAward Night, Satya Brahma, Chairman & Editor-In-Chief of Network 7 Media Group said  “Pharma Leaders™ , asia’s biggest media in healthcare communications in association with Network 7 Media Group undertook the gigantic task of identifying the Leader in Healthcare Innovations as it has been doing for years. The Primary factor that propelled the Jury is to look at the forward looking vision of the company coupled with the risk taking abilities & the visionary Leadership of steering the company in the complex business of healthcare where each day we are witnessing new competition, bigger challenges & ability to stay ahead of competition. With a modest beginning as a pharmaceutical distributor in 1973 by Dilip Surana’s late father Shri G.C.Surana, the meteoric rise of Microlabs as a Leading player in pharmaceutical business with a formidable basket of top products enjoying the strong patronage of medical doctors can be attributed to the fact that how Dilip spearheaded the strategy to make it big. Today Microlab  is ranked among the top 20 pharma companies in the country.Indeed Microlabs has become one of the top 5 pharma players in the diabetes sector in India. Hailing from a village near Jodhpur in Rajasthan, the low profile Dilip Surana together with brother Anand Surana have propelled the growth engine with tremendous speed & dedicated mindset & your initiatives in the social sector is also a case to reckon with as Dilip’s efforts to help the marginalized sections of the society is a sign of a true global Leader. Pharma Leaders™ salute the deep commitment to bring cheers in the humanity & the visionary commanding Leadership in taking Microlabs to the crescendo of success & achievements”.

The Award ceremony is scheduled at 07.00 PM on 26th December 2014 onwards at the Grand Jade Room of Hotel sahara Star, Mumbai, India. Like every year, this will be attended by more than 300 power packed Healthcare Leaders in all disciple in the glittering award night followed by cocktail & Dinner

Mr. Dilip Surana son of Late Shri G. C. Surana (Founder of Micro Labs Limited) joined the family business in 1985 at a young age of 21 years, and  rapidly absorbed the nuances of Corporate Management that grew the company rapidly into a global pharmaceutical enterprise specializing in life saving medicines. His early years in industry were marked by distinguished accomplishments and thus steering Micro Labs among the top ranking companies in the pharma sector. The AWACS ranking for the company has improved from over 100 in 1985 to 18 as on 2014.

Under his leadership, the company established world-class state-of-the-art research and manufacturing facilities covering Active Pharmaceutical Ingredients (APIs) and finished dosage forms as well as infrastructure for new drug discovery. He instilled the most stringent quality standards in his pharmaceutical enterprise. As a result, Micro Labs has to its credit, all the international regulatory approvals including US FDA, UK MHRA, Australian TGA etc., reflecting the high standards of quality and regulatory compliance of research and manufacturing facilities.

Dilip Surana  pioneered the concept of specialty – wise focused divisions in the Indian Pharmaceutical Industry and established various divisions that cater to special therapeutic segments in chronic disease management.

  • Carsyon – Cardicare specialty division in 1994
  • Synapse – Neurology Psychiatry division in 1995
  • Vision – Ophthalmology division in 1998
  • Gratia – Dermatology Division in 1998
  • Diabetic Task Force Diabetology division in 2005
  • Foresee – Nephrology Division in 2008
  • Micro Critical Care – Critical Care Division 2013

He is a regular participant in various international seminars and summits relating to Pharma industry. He is instrumental in inducting Senior Pharma veterans in the company, to bring in the much needed professionalism in the company. Recognizing the dynamism and contribution of Mr. Dilip Surana to the Pharmaceutical Industry, he has been honored as the ‘Dynamic Entrepreneur of the year 2010’, honoured as the ‘Great Son of karnataka’ by Governor of Karnataka his excellency HR Bhardwaj in 2011, honoured as ‘Most Dynamic Entrepreneur of the Year’ 2013 and ‘Entrepreneur of the year’ 2014.

Micro Labs Limited is a multi-faceted healthcare organization with a proficient marketing team, state-of-the-art manufacturing facilities and R&D centres that are at par with international standards. All this, robustly backed by a strong distribution network and path-breaking research work has placed us amongst India’s fast growing transnational healthcare organizations. Under the able leadership of Mr. Dilip Surana (Chairman & Managing Director) and Mr. Anand Surana (Director), Micro’s brand portfolio includes some of the topmost brands in various specialties like Cardiology, Diabetology, Anti-infectives, Ophthalmology, Pain, etc. Amidst our proud achievers is Dolo, an award-winning brand highly prescribed for fever management. Micro Labs has been ranked among top 17 (as per SMSRC July-Aug’14) in prescriptions and 19 in sales (as per AWACS Sept’14) in India. The group has its presence in over 30 countries, with ground level operations in 15 countries, exporting all major dosages in every therapeutic segment. Being one of the leading Indian healthcare providers in India, Micro Labs aims to be a prominent pharmaceutical player in regulated and non-regulated markets across the globe.The company is also at the forefront in social contribution, striving to be a model corporate citizen in terms of Environmental Protection & Social Initiatives with significant contributions in the areas of education and health.Micro Labs is poised to achieve unparalleled status in the global pharmaceutical industry. Backed by a profound and resolute vision, we now have our eyes set on attaining the $1 billion mark by 2016.


Abbott India, Sun Pharma, Lupin, GlaxoSmithKline & Cipla in tight contest at Pharmaleaders 2014 Awards in top categories

Abbott India, Sun Pharma, Lupin, GlaxoSmithKline & Cipla in tight contest at Pharmaleaders 2014 Awards in top categories

Powerful brand

Abbott India, Sun Pharma, Lupin, GlaxoSmithKline & Cipla in tight contest at Pharmaleaders 2014 Awards in top categories

The race to the coveted & credible award for India’s Most Admired & Powerful Brand, Corporate Practice, Investor Relations intensifies at 7th Annual Pharmaceutical Leadership Summit & Awards 2014 with a big voting in top four categories to select the Pharma leader in Indian Pharma industry

Tuesday,2nd November 2014, Mumbai, Maharashtra : Pharmaleaders is back again like every year with a bang & this time with a yet another message. The Message is very loud & clear. Healthcare has no substitutes & Pharmaleaders means business. With the new Modi Government at the Centre, Pharmaleaders is hopeful of a plethora of reforms to see india smiling both by companies & patients. Pharmaleaders voce the opinion of Less Regulation, Less Bureaucracy & more & more easing of business transactions. Unlike last year, this Summit is debating on two important Sessions. in a uniquely positioned full day program encompassing two themes “Make In India – Healthcare Reforms , Insurance,Innovations,Investments & Infrastructure” & Empowering India’s Developing Healthcare System – Investing the Healthcare Solutions of Tomorrow in difficult Times at the Sahara Star, Mumbai International Airport in Mumbai, India, on December,26th , 2014. This historic Summit is supported by the Government of India at the Centre & is actively supported  by the Ministry of Health &  Family Affairs, Govt of India, Ministry of Commerce Pharmaceuticals , Government of india & host of other trade bodies. With more than 20 categories in voting by the stakeholders which includes the professionals of the pharmaceutical industry, healthcare analysts, consumers, stock analysts, medical Practitioners, Consultants, Hospital & Nursing Homes, india’s top Pharma majors with a significant command in the market share such as Abbott India Limited, Sun Pharmaceutical Industries, Glaxo Smithkline, Cipla are running neck to neck to chose the selection.

Speaking on the awards & process mechanism that follows the voting trends, Satya Brahma, Chairman & Editor-In-Chief Pharmaleaders said,” Pharma Leaders Awards has an established record of leadership in research, innovation and in ongoing improvements to health services through strong healthcare leadership. These Awards seek to recognise outstanding health leadership by an individual or team resulting in positive change across the global health system. Pharma Leaders Awards attempt to  recognize outstanding individual and team contributions across priority areas selected by the Pharmaleaders Jury. The Pharma leaders  Award recognises outstanding leadership, by an individual or Companies for a distinctive recognition in a clear exhibition of top performances in various verticals.Now in its 7th year, Pharma Leaders Awards received entries from healthcare corporations, hospitals, Medical Professionals, Research Scientist, and other allied disciplines listed in the award categories.”

“Pharma Leaders Awards Grand Jury is comprised of a panel of international industry experts,  representing the top creative minds in the field of healthcare, pharma academia, policy formation & the representatives from the  government. Each year, in addition to online judging sessions, the Pharma Leaders Awards organizes live judging  sessions around the globe to review digital based works as well as collateral materials that support a campaign and which cannot be judged online. These live sessions hosted at prominent international healthcare communication agencies, allow jurors to examine in detail multi-paged works including: sales kits, direct mail, brochures, point of purchase displays, and annual reports. The live voting can be seen at”.

Indian Pharma industry is very competitive & the Road ahead For the Indian Pharma Sector is very tough given the regulatiory & pricing issue  Remaining  the Biggest challenges.Althe five players are strong in their respective therapeutic segments mainly consolidated after the biggest takeovers by Abbott India, Sun Pharma, Lupin, GlaxoSmithKline barring Cipla which continue to focus on internal branding of home grown products. Abbott India Limited is engaged in the discovery, development, manufacture and marketing of pharmaceutical, nutritional, hospital, and diagnostic products. It has six divisions. The Company’s products and therapeutics include Thyroid, Diabetes and Urology products includes Hytrin, Obimet, Thyrocab, Thyrocal D3 and Thyronorm; Pain Management products includes Brufen, Brugel and Bruspaz; Vitamins, include Multi- Vitamins combinations for diverse patient population; Anti-infectives products include portfolio comprises of various Antibiotics; Anaesthesia products includes Sevorane for induction and maintenance of general anaesthesia in adult and paediatric patients, for in-patient an outpatient surgery; Neonatology products includes Survanta and Others, include Allergy, Anti Coagulant, Cardiology, Immunology and Virology.

GlaxoSmithKline Pharmaceuticals product portfolio includes prescription medicines and vaccines. Its prescription medicines range across therapeutic areas, such as anti-infectives, dermatology, gynaecology, diabetes, cardiovascular disease and respiratory diseases. It also offers a range of vaccines, for the prevention of hepatitis A, hepatitis B, invasive disease caused by H, influenzae, chickenpox, diphtheria, pertussis, tetanus and others. Revolade is for the treatment of thrombocytopenia in adults with the blood disorder chronic immune thrombocytopenic purpura. The Company has two research and development (R&D) units, which include Chemistry Research & Development and Pharmaceutical Research & Development.

Cipla Limited introduced a number of new drugs and formulations, such as Adgain (vital nutritional supplement for hair loss); Capnea (caffeine citrate injection and oral solution) for apnoea of prematurity in infants; Caspogin (caspofungin acetate injection) for new antifungal for life-threatening fungal infections; Endobloc (ambrisentan tablets); Esomac (esomeprazole tablets); Evocort (formoterol and mometasone rotacaps)-new once-daily asthma controller therapy; Isablac (lactulose and isphaghula husk granules), and Ivabeat (ivabradine tablets) drug for coronary artery disease and chronic heart failure. In July 2013, the Company acquired Cipla Medpro South Africa Limited. In November 2013, the Company’s wholly owned step down subsidiary Meditab Holdings Limited, acquired an additional 14.5% interest in Quality Chemical Industries Limited (QCIL) and now held 51.05% interest in QCIL.

Sun Pharmaceutical Industries manufactures and markets pharmaceutical formulations as branded generics, as well as generics in India, the United states and several other markets across the world. The Company’s business is divided into four segments: US Generics, Indian Branded Generics, International Branded Generics (Rest of the world, except the US and India) and Active Pharmaceutical Ingredients (API). Its brands are prescribed in chronic therapy areas like cardiology, psychiatry, neurology, gastroenterology, diabetology and respiratory. It makes specialty APIs, including peptides, steroids, hormones and anticancers. The Company manufactures 170 APIs. It’s API products include Acamprosate Calcium, Alendronate Sodium, Amifostine trihydrate, Budensonide and Carvedilol. In July 2014, Sun Pharmaceutical Industries Ltd acquired Pharmalucence Inc.

Lupin produces a range of generic and branded formulations and bulk drugs. The Company along with its subsidiaries has manufacturing locations spread across India and Japan with trading and other incidental and related activities extending to world markets. The Company’s product basket consists of formulations from Cephalosporins, CVS, CNS, Anti-Asthma, Anti-TB, Diabetology, Dermatology, GI, and other therapy segments . The Company’s products include Cephalexin, Cefaclor, Ethambutol, Prasugrel, Rasagiline Mesylate, Lacosamide, and Febuxostat. Its brands include AKT 2, AKT3, AKURIT3, BUDAMATE 100 TRANSCAPS, BUDAMATE 100 HFA TRANSHALER, BUDATE 100 HFA TRANSHALER (MDI), and BUDATE 200 HFA TRANSHALER (MDI). The Company’s Drugs and products reach over 100 countries in the world. Effective February 2014, Lupin Ltd acquired Nanomi BV, a manufacturer of pharmaceutical products.

The Award ceremony is scheduled at 07.00 PM on 26th December 2014 onwards at the Grand Jade Room of Hotel sahara Star, Mumbai, India. Like every year, this will be attended by more than 300 power packed Healthcare Leaders in all disciple in the glittering award night followed by cocktail & Dinner.

Pharmaleaders is  India’s first opinion based & research driven bi-monthly magazine & has a decade of relentless reporting in Pharma Journalism in an unbiased, fearless & independent way. Over the last one decade, The Magazine has covered some of the biggest voices in healthcare Industry. Available both in digital & printed format, Pharmaleaders has emerged out as a leading title in voicing the opinion of the healthcare industry to the statutory Authorities like Ministry of Health & Family Affairs, Dept of Chemicals & Fertilizers, DCGA, FDA & many other institutions to present the pressing demands of the healthcare industry. Network 7 Media Group Media Outfit, a unit of Pharmaleaders, is a result of emergence of an extreme thought process in the form of some of the biggest & exclusive media properties that arose due to the frustration & disappointment of the present status-quo of the society in existence in the form of a careless & extremely insensitive administration of a large set-up. Network 7 Group has continuously strived to expose the misdeeds of the corrupt administrative fabrics or poor legislation or failure of a large entity in corporate governanance. Distinctively standing out of other media initiatives, Network 7 group has been in the forefront of championing the cause of good governance , fair, unbiased & independent reporting in national & international fields. Driven by the objective to address & deliberate some of the burning issues, sometimes neglected causes, Pharmaleaders is pioneering the concept of introducing a fierce democratic process in the form a mass resistance in bringing into the forefront of issues that matter most in the form of digital, printed, published, conclaves, summits & even in blogs & letters shoot out to the authoritative.  Headquartered in Mumbai, Network 7 Group Media Outfit is backed & operated by some of the biggest think-tanks of the contemporary society whose ideas & actions are reflected in the form of editorials & exclusive news findings. Network 7 Group Media is present in the form of digital media production, publications, high-profile international events & healthcare communications.

Media Contacts

Sangeeta Singh

Unit No.47, 2nd Floor, Aditya Industrial Estate,

CTS No. 1068-C, Plot No. 444(P),

Devrukhkar Wadi,Chincholi Bunder Road, Malad (W),

Mumbai–400064.+ 91 22 42481253, + 91 22 42481259

Mr Anish Khan : ++ 91 9819499475 :

Ms Sneha : ++ 91 9930583326   Web :